Synthomer Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Synthomer ont diminué à un taux annuel moyen de -56.6%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en à 19.8% par an. Les revenus ont augmenté de en baisse à un taux moyen de 5.2% par an.
Informations clés
-56.62%
Taux de croissance des bénéfices
-68.63%
Taux de croissance du BPA
| Chemicals Croissance de l'industrie | 4.35% |
| Taux de croissance des recettes | -5.22% |
| Rendement des fonds propres | -13.72% |
| Marge nette | -7.11% |
| Dernière mise à jour des bénéfices | 30 Jun 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Aug 17
SYNT: Higher Profitability Assumptions And Execution On Plans Will Support Future Upside
Analysts have trimmed their fair value estimate for Synthomer from £1.47 to £1.28, even as recent price target increases on the stock point to updated views on revenue growth, profitability and future P/E assumptions. Analyst Commentary Recent research on Synthomer gives investors a mixed message.Article d’analyse • Aug 08
Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results
Shareholders will be ecstatic, with their stake up 39% over the past week following Synthomer plc 's ( LON:SYNT...
Mise à jour du récit • Aug 03
SYNT: Higher Fair Value And Execution Risks Will Shape Future Earnings
Analysts have raised their price target on Synthomer to £0.92 from £0.62, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key factors supporting the new level. Analyst Commentary Recent research updates on Synthomer suggest that, while targets have been adjusted, many analysts remain cautious about the stock.
Mise à jour du récit • Jul 20
SYNT: Recent Price Objective Revisions Will Shape A More Constructive Outlook
The Analyst Price Target on Synthomer has been adjusted from £3.48 to £2.00 per share, reflecting analysts' updated assumptions on fair value, discount rate, and earnings profile in light of recent price target increases from £0.62 to £0.92 and an additional £0.40 uplift cited in Street research. Analyst Commentary Recent Street research on Synthomer points to a more constructive tone, with bullish analysts revisiting their fair value assumptions and revising price targets.Mise à jour du récit • Jul 06
SYNT: Cost Actions And Execution On Plans Will Support Future Upside
Analysts have lifted their fair value estimate for Synthomer from £1.27 to £1.47, reflecting higher price targets from the Street and updated assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street commentary on Synthomer points to a more constructive stance on the stock, with price targets moving higher and ratings generally sitting in the neutral range.Mise à jour du récit • Jun 22
SYNT: Leadership Change And Higher Risk Profile Will Pressure Future Earnings
Analysts have lifted their price target on Synthomer by £0.40, citing updated assumptions around discount rates, revenue growth and future P/E that they view as better aligned with the company’s current risk and earnings profile. What’s in the News for Synthomer Synthomer announced that Chief Financial Officer Lily Liu plans to step down to become Executive Vice President and Chief Financial Officer at Umicore SA.Mise à jour du récit • Jun 06
SYNT: Leadership Transition Will Intensify Concerns Over Future Margin Stability
Analysts have nudged Synthomer's fair value higher, lifting the implied price target from £0.59 to £0.62. This reflects refreshed assumptions on revenue growth, discount rate and future P/E.Mise à jour du récit • May 04
SYNT: Bio-Based Shift Will Face Margin And Leadership Risks Ahead
Analysts have kept their Synthomer fair value target steady at £0.59. This reflects a view that a shift from a previous revenue contraction of 32.37% to expected growth of 2.61%, together with a slightly lower projected profit margin of 9.99%, leaves the overall valuation framework broadly unchanged.Mise à jour du récit • Apr 20
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.Mise à jour du récit • Apr 06
SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).Mise à jour du récit • Mar 23
SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.Mise à jour du récit • Mar 09
SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).Mise à jour du récit • Feb 22
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.Mise à jour du récit • Feb 08
SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).Mise à jour du récit • Jan 24
SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.Mise à jour du récit • Jan 10
SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.Mise à jour du récit • Dec 24
SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.Mise à jour du récit • Dec 10
SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.Mise à jour du récit • Nov 26
SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.Mise à jour du récit • Nov 07
SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Mise à jour du récit • Oct 24
Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.Article d’analyse • Aug 09
UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
There's been a major selloff in Synthomer plc ( LON:SYNT ) shares in the week since it released its half-year report...Mise à jour du récit • Aug 07
Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.
Nouveau récit • Mar 31
Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Article d’analyse • Jan 08
Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Synthomer plc's ( LON:SYNT ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Article d’analyse • Oct 05
Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
You may think that with a price-to-sales (or "P/S") ratio of 0.2x Synthomer plc ( LON:SYNT ) is a stock worth checking...Article d’analyse • Aug 03
Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£2.63 With UK£2.46 share...Article d’analyse • Jun 18
Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d’analyse • May 25
Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
Synthomer plc ( LON:SYNT ) shares have continued their recent momentum with a 27% gain in the last month alone. Still...Article d’analyse • Apr 20
Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£1.84 Current share price...Article d’analyse • Mar 14
Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Synthomer plc ( LON:SYNT ) shareholders would be excited to see that the share price has had a great month, posting a...Article d’analyse • Feb 08
Should You Think About Buying Synthomer plc (LON:SYNT) Now?
While Synthomer plc ( LON:SYNT ) might not have the largest market cap around , it saw a double-digit share price rise...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Synthomer gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 26 | 1,799 | -128 | 187 | 0 |
| 31 Mar 26 | 1,769 | -139 | 183 | 0 |
| 31 Dec 25 | 1,739 | -150 | 180 | 0 |
| 30 Sep 25 | 1,755 | -107 | 187 | 0 |
| 30 Jun 25 | 1,802 | -71 | 195 | 0 |
| 31 Mar 25 | 1,868 | -72 | 195 | 0 |
| 31 Dec 24 | 1,933 | -72 | 195 | 0 |
| 30 Sep 24 | 1,926 | -79 | 181 | 0 |
| 30 Jun 24 | 1,919 | -86 | 167 | 0 |
| 31 Mar 24 | 1,930 | -96 | 167 | 0 |
| 31 Dec 23 | 1,941 | -105 | 167 | 0 |
| 30 Sep 23 | 2,046 | -127 | 165 | 0 |
| 30 Jun 23 | 2,151 | -149 | 163 | 0 |
| 31 Mar 23 | 2,242 | -84 | 163 | 0 |
| 31 Dec 22 | 2,332 | -18 | 163 | 0 |
| 30 Jun 22 | 2,143 | 80 | 171 | 0 |
| 31 Mar 22 | 2,143 | 139 | 171 | 0 |
| 31 Dec 21 | 2,144 | 198 | 172 | 0 |
| 30 Sep 21 | 2,235 | 213 | 187 | 0 |
| 30 Jun 21 | 2,141 | 217 | 183 | 0 |
| 31 Mar 21 | 1,892 | 110 | 183 | 0 |
| 31 Dec 20 | 1,644 | 3 | 183 | 0 |
| 30 Sep 20 | 1,537 | 14 | 141 | 0 |
| 30 Jun 20 | 1,430 | 24 | 100 | 0 |
| 31 Mar 20 | 1,445 | 54 | 100 | 0 |
| 31 Dec 19 | 1,459 | 85 | 100 | 0 |
| 30 Sep 19 | 1,503 | 81 | 108 | 0 |
| 30 Jun 19 | 1,548 | 77 | 116 | 0 |
| 31 Mar 19 | 1,583 | 89 | 116 | 0 |
| 31 Dec 18 | 1,619 | 100 | 116 | 0 |
| 30 Sep 18 | 1,581 | 101 | 115 | 0 |
| 30 Jun 18 | 1,544 | 102 | 113 | 0 |
| 31 Mar 18 | 1,512 | 88 | 114 | 0 |
| 31 Dec 17 | 1,480 | 74 | 114 | 0 |
| 30 Sep 17 | 1,425 | 90 | 106 | 0 |
| 30 Jun 17 | 1,370 | 105 | 99 | 0 |
| 31 Mar 17 | 1,208 | 108 | 99 | 0 |
| 31 Dec 16 | 1,046 | 110 | 99 | 0 |
| 30 Sep 16 | 954 | 95 | 88 | 0 |
| 30 Jun 16 | 862 | 79 | 77 | 0 |
| 31 Mar 16 | 866 | 70 | 76 | 0 |
| 31 Dec 15 | 870 | 60 | 76 | 0 |
| 30 Sep 15 | 892 | 56 | 66 | 0 |
Des revenus de qualité: SYNT n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: SYNT n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: SYNT n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 56.6% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de SYNT au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: SYNT n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Chemicals ( 31.6% ).
Rendement des fonds propres
ROE élevé: SYNT a un retour sur capitaux propres négatif ( -13.72% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/17 03:17 |
| Cours de l'action en fin de journée | 2026/09/17 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Synthomer plc est couverte par 14 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Sebastian Bray | Berenberg |
| Rikin Patel | BNP Paribas |
| Kevin Fogarty | Deutsche Bank |